Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Genetic Test Determines Melanoma Severity
Clinical Breakthroughs

Genetic Test Determines Melanoma Severity

By Roger AndersonOct 14, 2013
Share
Facebook Twitter Email
The American Cancer Society estimates that 76,690 new melanomas will be diagnosed in the United States this year.

Knowing which melanomas are likely to be cured with surgery and which are likely to spread is the basis for a new clinical test recently validated by Pedram Gerami, MD, associate professor in dermatology and pediatrics-dermatology.

“The significance of this study is that we can provide patients and their healthcare providers greater accuracy than before in predicting how melanomas, the most dangerous form of skin cancer, will react,” said Gerami, director of melanoma research at the Northwestern Skin Cancer Institute and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “These findings give us one additional way to characterize melanomas, classify them, and allow us to fine tune treatment plans for individual needs.”

Gerami’s data, disseminated at the Summer Academy Meeting of the American Academy of Dermatology, confirmed previous studies that showed a specific genetic test was a strong predictor of which Stage I or II non-metastatic skin cancers will likely recur.

“The test will help save some patients with low-grade melanomas part of the undue burden of certain treatments used in aggressive melanomas and likewise make sure patients who do have aggressive disease get the treatment they need,” Gerami said.

Gerami’s lab uses molecular techniques to improve diagnosis and prognosis in melanomas. He recently published a protocol for determining whether a tumor is melanoma or not when standard microscopy – a common way to diagnose the disease – fails to do so. The lab is currently evaluating an adhesive skin tape to non-invasively evaluate genetic material from moles.

The validation data confirm previous studies showing that the gene expression profile test is a strong independent predictor for classifying which Stage I or II non-metastatic cutaneous melanoma patients will likely recur. The results were presented by Pedram Gerami, M.D., Associate Professor of Dermatology, Director of Melanoma Research at the Northwestern Skin Cancer Institute, Northwestern University.

The multi-institutional validation study included archived tumors at Northwestern from nearly 240 Stage I and II melanoma patients. It was funded by Castle Biosciences Inc.

Cancer Dermatology Genetics Research
Share. Facebook Twitter Email

Related Posts

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023

Combination Immunotherapy Shows No Additional Benefit for Most Advanced Cancers

Sep 21, 2023

Novel Intracellular Signaling Mechanisms Promote Melanoma Growth

Sep 21, 2023

Comments are closed.

Latest News

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023

Robert Lamb, Renowned Expert on Influenza Virus, Dies at 72

Sep 22, 2023

Bethany Ekesa, Associate Director of SPARC, Honored with Jean E. Shedd University Citizenship Award

Sep 21, 2023

Combination Immunotherapy Shows No Additional Benefit for Most Advanced Cancers

Sep 21, 2023

Novel Intracellular Signaling Mechanisms Promote Melanoma Growth

Sep 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230914_NM461
20230914_NM644
20230914_NM345
20230914_NM444
20230914_NM464
20230914_NM520
20230914_NM673
20230914_NM641
20230914_NM612
20230914_NM608
20230914_NM602
20230914_NM597

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.